Table 3.
Mean time to normalization according to outcome: Days (SD)
| Positive outcome a | N a (%) | Negative outcome a | N a (%) | |
|---|---|---|---|---|
| Total patients | 15 | 8 | ||
| Lymphocytes | 12 (7.7) | 9 (60%) | 22 (5.3) | 3 (37.5%) |
| B lymphocytes | 2.9 (4.9) | 10 (66%) | 5.0 (5.8) | 4 (50%) |
| T lymphocytes | 12 (9.4) | 10 (66%) | 23 (7) | 2 (25%) |
| CD4+ T lymphocytes | 7.3 (7) | 12 (80%) | 16 (20) | 5 (62.5%) |
| CD8+ T lymphocytes b | 19 (7) | 6 (40%) | 52 (0) | 1 (12.5%) |
| CD8+ T lymphocytes (twofold increase) | 12 (12) | 12 (80%) | 20 (18) | 6 (75%) |
| NK cells | 3.4 (10) | 10 (66%) | 8.8 (2.9) | 5 (62.5%) |
Only patients reaching normal values were included in this analysis. Single abrupt elevations followed by abnormal values were not counted as normalization.
Only one patient in the group with negative outcome reached normal CD8+ values.
In the group with positive outcome, two patients were lost to follow‐up after hospital discharge with only two measures at the point of censoring.
Normal values according to local laboratory definitions: Lymphocytes > 1500 cells/μL, B lymphocytes > 150/μL, T lymphocytes > 950/μL, CD4+ T lymphocytes > 550/μL, CD8+ T lymphocytes > 500/μL, NK cells > 80/μL.
SD, standard deviation.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.